Rajiv Gandhi Cancer Institute and Research Centre

Institution (Healthcare)

Homepage ROR

Also Known As

RGCI & RC, Rajiv Gandhi Cancer Institute and Research Centre

2.3K

Publications

56.2K

Citations

307

Authors

300

Concepts

About

Rajiv Gandhi Cancer Institute and Research Centre is a healthcare institution in New Delhi, India known for medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	17	150	3.5K
2	Engineering	13	44	1.3K
3	Arts	1	1	11
4	Language Studies	1	1	11
5	Management	1	1	108

Rajiv Gandhi Cancer Institute and Research Centre

2.3K

Publications

56.2K

Citations

Page 1

	Year	Citations
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study Bella Kaufman, John R. Mackey, Michael Clemens, Journal of Clinical Oncology	2009	848
A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009–17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance Anuradha Chowdhary, Anupam Prakash, Cheshta Sharma, Journal of Antimicrobial Chemotherapy	2017	558
Reduced graphene oxide modified smart conducting paper for cancer biosensor Saurabh Kumar, Suveen Kumar, Saurabh Srivastava, Biosensors and Bioelectronics Materials ScienceGraphene NanomeshesGraphene Quantum DotCancer BiosensorEngineering	2015	172
Biofunctionalized Nanostructured Zirconia for Biomedical Application: A Smart Approach for Oral Cancer Detection Suveen Kumar, Saurabh Kumar, Sachchidanand Tiwari, Advanced Science	2015	141
A Phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer Dinesh Chandra Doval, Jagdev Singh Sekhon, Sunil K. Gupta, British Journal of Cancer	2004	136
Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial Joseph Gligorov, Dinesh Doval, José Bines, The Lancet Oncology Breast OncologyOncologyMaintenance CapecitabineInitial First-line BevacizumabBreast Cancer	2014	126
A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study Jun Yi, Sumitra Thongprasert, Dinesh Chandra Doval, European Journal of Cancer Second-line TreatmentMedicineHepatobiliary TumorBiliary CancerPhase Ii Study	2011	119
Highly sensitive protein functionalized nanostructured hafnium oxide based biosensing platform for non-invasive oral cancer detection Suveen Kumar, Saurabh Kumar, Sachchidanand Tiwari, Sensors and Actuators B Chemical NanomedicineNanostructured Hafnium OxideSensitive ProteinEngineeringBiosensing Systems	2016	109
Information Technology and Broad-Based Development: Preliminary Lessons from North India Priyanka Kaushik, Nirvikar Singh World Development Business IntelligenceInformation Technology ConvergenceInformation Technology ManagementDesignManagement	2004	108
First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study Olavo Feher, P Vodvářka, Jacek Jassem, Annals of Oncology Metastatic Breast CancerOncologyBreast OncologyMedicineBreast Cancer	2005	93

Page 1